Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-08Clinical Trial Update: Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. [Phase 3]
A Phase 3 clinical trial evaluated erlotinib and docetaxel in non-small cell lung cancer patients stratified by VeriStrat status; results co…
-
CLINICAL_TRIALS trial_result · 2019-08-07Clinical Trial Update: Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases [Phase 2]
Phase 2 trial update evaluating risk-adapted SABR for Stage I non-small cell lung cancer and lung metastases.
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) [Phase 1]
Phase 1 study evaluating nivolumab in combination with various chemotherapies or as monotherapy for advanced non-small cell lung cancer; tri…
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating Erlotinib or Crizotinib in combination with chemoradiation for Stage III non-small cell lung cancer; study termi…
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer [Phase 2]
Phase 2 trial update evaluating gefitinib, AZD9291, or selumetinib plus docetaxel, or an initial immune-mediated therapy with a sequential s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Palliative Thoracic Radiotherapy Plus BKM120 [Phase 1]
Phase 1 trial evaluating palliative thoracic radiotherapy combined with BKM120 in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: A Phase I/II Trial of Stereotactic Body Radiation Therapy [Phase 1, Phase 2]
Phase I/II trial evaluating stereotactic body radiation therapy for inoperable stage I/II non-small cell lung cancer completed with results …
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy [Phase 3]
Phase 3 open-label trial evaluating rociletinib versus single-agent cytotoxic chemotherapy in EGFR-mutant NSCLC after prior EGFR-TKI and pla…
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating daratumumab in combination with atezolizumab versus atezolizumab alone in previously treated advanced or metast…
-
CLINICAL_TRIALS research · 2019-07-19Clinical Trial Update: Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Retrospective epidemiology study assessing ALK rearrangement in non-small cell lung cancer patients in the Middle East and North Africa.
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing Alectinib with Crizotinib and assessing pharmacokinetics in Asian participants with treatment-naive ALK-positive adv…
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing alectinib to crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer completed with results p…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients [Phase 3]
Phase 3 trial comparing icotinib to first-line chemotherapy with maintenance in EGFR-positive lung adenocarcinoma; completed study.
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC [Phase 1, Phase 2]
Phase 1b/2 study investigating rociletinib in combination with MPDL3280A in advanced/metastatic EGFR-mutant non-small cell lung cancer was t…
-
CLINICAL_TRIALS trial_result · 2019-07-01Clinical Trial Update: Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients [Phase 1]
Phase 1 trial update on crizotinib plus pembrolizumab in ALK-positive advanced non-small cell lung cancer; study terminated with results pos…
-
FDA approval · 2019-06-27FDA Approved: ZIRABEV — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves ZIRABEV (bevacizumab-bvzr) from Pfizer as a biosimilar to Avastin under an Original Application. The approval covers multiple b…
-
FDA approval · 2019-06-25FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for XALKORI (crizotinib) filed by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 trial comparing IV topotecan/docetaxel combination vs docetaxel alone as second-line therapy in advanced non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2019-06-20Clinical Trial Update: Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. [Phase 3]
A Phase 3 clinical trial evaluating a combination therapy of Ectiecinib, Pemetrexed, and Platinum in metastatic non-squamous non-small cell …
-
CLINICAL_TRIALS trial_result · 2019-06-20Clinical Trial Update: Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma [NA]
A terminated clinical trial investigating expression analysis of specific markers in non-small cell lung cancer and melanoma; results posted…
-
CLINICAL_TRIALS trial_result · 2019-06-19Clinical Trial Update: Efficacy Study of Vx001 Vaccine in NSCLC Patients [Phase 2]
Phase 2 efficacy study of Vx001 vaccine in metastatic non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-06-19Clinical Trial Update: Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial of metformin as chemoprevention in non-small cell lung cancer was terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC [Phase 2]
A Phase 2 randomized study evaluating primary tumor radiotherapy for patients with malignant pleural effusion in stage IV non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) [Phase 1]
Phase I trial evaluating afatinib and dasatinib in non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-06-13Clinical Trial Update: Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating nivolumab and epacadostat plus platinum doublet chemotherapy versus platinum doublet chemotherapy in non-small cell…